Oncology

This technology is a method to generate squamous epithelial 3D organoids that can mimic the natural physiology of tissues and be used as a personalized pathology model.

This technology provides methods for treating myelofibrosis using targets that deplete or inhibit the expansion of Sox10+ and ErbB3+ glial cells.

This technology is patient-specific engineered model of bone marrow for diagnostics and research of cancer progression using a sample of patient’s serum.

This technology is a bioengineered bone marrow system that can be applied to study various human diseases, toxicity responses, and immune functions in vitro.

This technology is a computational pipeline designed to identify major kinases in different cancer subtypes for the development of precision cancer therapeutics.

This technology is an optical catheter method for the analysis of uterine tissue using spectrometry without removing a sample from the patient.

This technology is a modular platform with engineered tissues linked by vascular perfusion that can be used to study tumor progression and systemic disease in a clinically relevant setting.

This technology is a SLAMF6 bispecific antibody to enhance T-cell activation through compartmentalization that can be used for tumor treatments.

This technology assesses the role of irradiation therapy for cancer treatment and its impact on adenosine signaling.

This technology is a probiotic nanoencapsulation system to enhance the efficacy and safety of probiotic administration.

This technology describes the mechanism of action and use of compound FIN56, a specific inducer of ferroptosis.

This technology uses computational methods to identify the cell of origin and differentiation path leading to the formation of a particular type of cancer-associated fibroblasts (“aCAFs,” standing for aggressive cancer-associated fibroblasts), as well as related pan-cancer targets for therapeutic development.

This technology is two methods, called ssg-MeDIP-Seq and sscf-MeDIP-Seq, for improved tumor detection using detection of DNA methylation density in genomic DNA, and of hemi-methylated regions in plasma cell-free DNA.

This technology is a cancer immunotherapy platform that activates CD28-CD8+ T-cells via the CD58:CD2 axis.

Hypoxia is a characteristic feature of glioblastoma, as well as many other malignant tumors, and is associated with poor patient prognosis.